Laxman Byreddi

Laxman Byreddi practices at Lifecare Hospitals of Shreveport - Main Campus (Closed) in Shreveport, Louisiana.

Laxman Byreddi's NPI, 1932695087, was assigned on July 2, 2018. Laxman Byreddi holds Louisiana license 327370.

Laxman Byreddi's primary practice is Lifecare Hospitals of Shreveport - Main Campus (Closed), at 1541 Kings Hwy, Shreveport, LA 71103 in Caddo Parish. The practice phone is (972) 464-0022.

Laxman Byreddi's primary practice is Lifecare Hospitals of Shreveport - Main Campus (Closed) in Shreveport, Louisiana. The medical group on file is LSU Health Shreveport.

Dmand AI tracks the electronic health record (EHR) system at each site where Laxman Byreddi practices. Vendor and product names are available with a free account.

Hospitalist is Laxman Byreddi's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Laxman Byreddi is licensed in Louisiana.

CMS data shows 482 Medicare services from Laxman Byreddi across 4 procedure codes in 2024, for 157 Medicare patients. Medicare paid $37,063 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 157 Medicare patients who saw Laxman Byreddi in 2024. The largest group is under 65, with 50 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 50% are also on Medicaid. Their average risk score is 2.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Laxman Byreddi's median patient age at 65, with 32% women.

In 2024, Laxman Byreddi wrote 74 Medicare Part D claims for 26 patients. 89% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $2,450 in total drug cost. In 2022, CMS named 16 claims across 1 drug.

Dmand AI links 6 papers to Laxman Byreddi, published from 2021 to 2025. 2025 was the busiest year, with 3. Laxman Byreddi has published most often in J Natl Compr Canc Netw. Laxman Byreddi's most frequent co-authors are Shafaqat Ali, MD, Arunima Dutta, MD and Kavitha D. Kesari, MD.

CMS Open Payments shows 14 general payments to Laxman Byreddi from 6 drug and device companies from 2021 to 2025. Grants make up the largest share, 77% of the total. Merck Sharp & Dohme Corporation paid the most, $1,000.